PubMed Triage Digest — 2026-07-23

Run ID: 2026-07-23-attempt3-20260723T093927Z Attempt: 3 of 3 (schema repair from attempt 2 salvage) Search window: 2026-07-22 → 2026-07-23 (CRDT) Articles emitted: 16 (11 HIGH, 5 STANDARD) Run status: SUCCESS Model: anthropic/claude-sonnet-4-6

Executive Summary

Today's scan surfaces a notably strong day for immunotherapy mechanistic science, with four Science Translational Medicine papers published simultaneously. The standout findings are: a novel VIP-VIPR armored CAR-T strategy (score 9), engineered bacteria probiotic immunotherapy for bladder cancer (score 9), a paradigm-shifting discovery that IL-6R blockade (tocilizumab) promotes cytolytic CD4+ T cells during HSCT (score 9), and first single-cell RNAseq evidence of SGLT2i renoprotection in youth with T1D from an RCT (score 9). In hematology, Cancer Discovery reports the molecular basis of pan-BTK resistance (A428D mutation) in CLL patients on BTK degrader trials—immediately relevant for ongoing trials and next-generation therapy design. In rare diseases, Science Translational Medicine shows senolytic agents reverse premature HSC dysfunction in sickle cell disease, offering a translatable path to improve gene therapy outcomes.

No articles found for CBC/ML diagnostics (Topic 2) — zero qualifying publications in the 24-hour window (extended fallback to 2026-07-21 also returned nothing).

Coverage Statistics

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Novel Therapeutics

[PMID 42485431] 🟠 NOVEL_TREATMENT Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Lin HK, Blake DA, Freeman R et al. Science Translational Medicine 2026 Jul 22. DOI: 10.1126/scitranslmed.adt9565

Key finding: Armored CAR T cells (CAR/VIPRa) secreting a VIPR antagonist peptide maintain memory phenotype, potentiate endogenous antitumor immunity via host T cell recruitment, and achieve superior tumor control in syngeneic and xenogeneic models of both hematological and solid tumors. Why it matters: VIP is an immunosuppressive neuropeptide that limits CAR-T function; engineering CAR-T cells to neutralize it in situ simultaneously addresses poor product phenotype and lack of endogenous immune engagement—two of the hardest CAR-T problems. Scores: Novelty 3 | Relevance 3 | Design Quality 2 | Unmet Need 1 = 9/10 Evidence: Exploratory (preclinical) | Species: mixed | Confidence: high

[PMID 42485436] 🟠 NOVEL_TREATMENT Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models. Rouanne M, Chen N, Mariuzza DL et al. Science Translational Medicine 2026 Jul 22. DOI: 10.1126/scitranslmed.adv7600

Key finding: CXCL13-expressing E. coli Nissle 1917 (EcN), delivered intravesically, colonizes bladder tumors, induces germinal center responses in tumor-draining lymph nodes, elicits tumor-specific antibodies, and improves anti-PD-1 efficacy with long-term survival and protective immunity in two immunologically cold orthotopic bladder cancer models. Why it matters: First demonstration that a synthetic-biology probiotic bacteria can convert an immunologically cold tumor to immunotherapy-responsive via humoral immune amplification; provides a manufacturable combination strategy for bladder cancer. Scores: Novelty 3 | Relevance 3 | Design Quality 2 | Unmet Need 1 = 9/10 Evidence: Exploratory (preclinical) | Species: animal | Confidence: high

[PMID 42485668] 🟠 NOVEL_TREATMENT IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy. Williams C, Zhang P, Adams RC et al. Blood 2026 Jul 22. DOI: 10.1182/blood.2025032420

Key finding: Single-cell RNAseq of clinical trial samples (tocilizumab vs placebo during allogeneic HSCT) showed IL-6R inhibition promotes Type-I IFN programs and cytolytic Eomes+ CD4+ T cell differentiation; in experimental HSCT and CAR-T systems, genetic IL-6 deletion enhanced cytolytic CD4+ expansion and antitumor effects. Why it matters: Paradigm-shifting: tocilizumab, widely used as an immunosuppressant for GVHD, paradoxically enhances cytolytic antitumor CD4+ T cell differentiation; if validated, this could transform it into a dual GVHD prophylaxis + antitumor enhancement agent. Scores: Novelty 3 | Relevance 3 | Design Quality 2 | Unmet Need 1 = 9/10 Evidence: Exploratory (clinical trial + mechanistic) | Species: mixed | Confidence: high

[PMID 42485107] 🟠 NOVEL_TREATMENT Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in r/r CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial. Wang X, Zhang Q, Yan D et al. Clinical Cancer Research 2026 Jul 22. DOI: 10.1158/1078-0432.CCR-26-1292

Key finding: 44 patients with r/r CD30+ lymphoma (33 Hodgkin): ORR 95.5%, CR rate 52.3%; 3-year OS 79.0%, PFS 74.2%; auto-HSCT consolidation after CAR-T improved best CR (75% vs 45%) and significantly prolonged OS/PFS vs CAR-T alone. Scores: Novelty 1 | Relevance 3 | Design Quality 2 | Unmet Need 2 = 8/10 Evidence: Validated (phase 1/2 clinical trial) | Species: human | Confidence: high

[PMID 42485358] ⚪ PROMISING_PRELIMINARY In vitro inhibition of STAT5 signaling limits CD8+ T cell exhaustion and improves outcomes in adoptive T-cell therapy. Shourian M, Bourdin B, El-Hachem N et al. Cancer Immunology Research 2026 Jul 22. DOI: 10.1158/2326-6066.CIR-25-1493

Key finding: Transient STAT5 inhibition during ex vivo T cell expansion enriches TCF1+Ly108+ progenitor-like CD8+ T cells while preserving cytotoxicity; STAT5i cells showed superior tumor control in vivo and preserved memory-progenitor phenotypes in human CD22 CAR T cells. Scores: Novelty 2 | Relevance 3 | Design Quality 2 | Unmet Need 1 = 8/10 Evidence: Exploratory (preclinical + human in vitro) | Species: mixed | Confidence: high

Hematologic Malignancies

[PMID 42484277] 🟠 NOVEL_TREATMENT Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors. Sievers Q, Lu H, Cool A et al. Cancer Discovery 2026 Jul 22. DOI: 10.1158/2159-8290.CD-26-0251

Key finding: BTK A428D mutation—identified from serial samples of CLL patients on phase I BTK degrader trials—confers pan-resistance to all BTK inhibitors AND degraders via structural clash with the adenine-mimetic moiety; A428D cells have competitive disadvantage off BTK-directed therapy; venetoclax combination mitigates A428D expansion. Why it matters: First pan-BTK resistance mechanism identified from active clinical trials; provides structural rationale for next-generation BTK therapy design and an immediate clinical counterstrategy (add venetoclax). Scores: Novelty 3 | Relevance 3 | Design Quality 2 | Unmet Need 1 = 9/10 Evidence: Validated (clinical observational + crystallography) | Species: human | Confidence: high

[PMID 42485357] ⚪ PROMISING_PRELIMINARY The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy. Hu K, Jin L, Feng Z et al. Cancer Immunology Research 2026 Jul 22. DOI: 10.1158/2326-6066.CIR-25-1230

Key finding: Turicibacter and Parvibactor identified as critical gut microbiome species determining CAR-T efficacy; supplementation enhanced endogenous CD8+ T cell activation and antitumor efficacy in syngeneic CD19+ lymphoma. Scores: Novelty 2 | Relevance 2 | Design Quality 2 | Unmet Need 2 = 8/10 Evidence: Exploratory (preclinical) | Species: animal | Confidence: high

Cardiometabolic

[PMID 42485434] 🟢 NEAR_TERM_IMPLEMENTABLE SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Bjornstad P, Choi YJ, Narongkiatikhun P et al. Science Translational Medicine 2026 Jul 22. DOI: 10.1126/scitranslmed.aee1005

Key finding: The ATTEMPT RCT (n=98 youths, ages 12–21 with T1D and hyperfiltration) showed dapagliflozin produced coordinated transcriptional improvements across proximal tubule, endothelial, and podocyte compartments by single-cell RNAseq (214,415 cells/27 biopsies), shifted >55% of T1D-dysregulated kidney genes toward healthy controls, and attenuated hyperfiltration. Why it matters: First RCT-based mechanistic evidence of SGLT2i renoprotection in youth with T1D—a population where kidney protection was previously unestablished—with single-cell resolution providing pathway-level insights. Scores: Novelty 3 | Relevance 2 | Design Quality 2 | Unmet Need 2 = 9/10 Evidence: Potentially Practice-Changing (RCT) | Species: human | Confidence: high

Aging / Longevity → Rare Diseases

[PMID 42485438] 🟠 NOVEL_TREATMENT Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Barve A, Dabas P, Cornwell A et al. Science Translational Medicine 2026 Jul 22. DOI: 10.1126/scitranslmed.adv0628

Key finding: SCD HSPCs from mice and patients exhibit oxidative stress, DNA damage, and senescence hallmarks with markedly reduced repopulating capacity; senolytic therapy (navitoclax or dasatinib+quercetin) reverses HSPC dysfunction both in SCD mice in vivo and in human SCD bone marrow ex vivo. Why it matters: Establishes premature HSC senescence as a mechanistically targetable driver of poor gene therapy outcomes in SCD; both senolytics used are clinically available agents offering an immediate translational path to improve curative gene therapy trials. Scores: Novelty 3 | Relevance 2 | Design Quality 2 | Unmet Need 2 = 9/10 Evidence: Exploratory (preclinical + human correlate) | Species: mixed | Confidence: high

Precision Oncology

[PMID 42485699] 🟢 NEAR_TERM_IMPLEMENTABLE Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer. Cruellas M, Rodriguez-Hernandez A, Carita L et al. ESMO Open 2026 Jul 22. DOI: 10.1016/j.esmoop.2026.108335

Key finding: Germline BRCA2 PVs independently associated with markedly shorter PFS on first-line CDK4/6i+ET (median 11 vs 27 months; aHR 2.73); endocrine-sensitive BRCA2 patients had aHR 4.04; RB1 LOH prevalent in BRCA2 tumors pre-treatment. Scores: Novelty 2 | Relevance 3 | Design Quality 1 | Unmet Need 2 = 8/10 Evidence: Validated (retrospective multicenter) | Species: human | n=233 | Confidence: high

Early Cancer Detection

[PMID 42485532] 🔴 EARLY_CANCER_DETECTION Systematic verification of saliva-based biosignatures for oral cancer via targeted metabolomics. Hsieh YJ, Chang Y, Yang C et al. Journal of Food and Drug Analysis 2026 Jun 1. DOI: 10.38212/2224-6614.3586

Key finding: Four-metabolite salivary panel (cadaverine, N-acetylcadaverine, choline, glycine) achieves AUC=0.91 for OSCC vs healthy controls (n=299); polyamine pathway reprogramming validated as OSCC metabolic hallmark across OPMD and OSCC stages. Why it matters: Well-powered non-invasive saliva-based cancer detection with progressive disease-stage correlation; directly addresses clinical gap for accessible OSCC screening. Scores: Novelty 2 | Relevance 2 | Design Quality 1 | Unmet Need 2 = 7/10 (HIGH via EARLY_CANCER_DETECTION flag) Evidence: Validated (diagnostic case-control) | Species: human | n=299 | Confidence: high

🟢⚪ STANDARD (5–7) — Top by Topic

Cardiometabolic / Rare Diseases (Sentinel)

[PMID 42485712] 🟢 NEAR_TERM_IMPLEMENTABLE · Score 7/10 Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality. Spencer-Bonilla G, Fan J, Varshney AS et al. JACC Advances 2026 Jul 22. DOI: 10.1016/j.jacadv.2026.103019 Each 1-year ATTR-CM diagnostic delay = 7% increased death/HFH risk (Medicare HR 1.07; VHA HR 1.07); n=10,327 combined. Large two-cohort real-world evidence quantifying the cost of diagnostic delay where tafamidis is available.

AI/ML Diagnostics

[PMID 42484890] 🟢 NEAR_TERM_IMPLEMENTABLE · Score 7/10 Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy. Immanuel C, Buttner T, Sprinkart AM et al. European Journal of Nuclear Medicine and Molecular Imaging 2026 Jul 22. DOI: 10.1007/s00259-026-08068-x AI-derived SMD (cutoff 19.26 HU) from routine PET/CT independently predicted OS in 410 mCRPC patients on PSMA-RLT (median OS 7.6 vs 12.2 months; HR 1.87). | Diagnostics

[PMID 42484847] ⬜ NONE · Score 5/10 Multiparametric MRI-based multi-channel deep learning model for accurate preoperative prediction of perineural invasion in lymph node-negative rectal cancer. Cheng D, Zhao J, Liu Z et al. Abdominal Radiology 2026 Jul 22. DOI: 10.1007/s00261-026-05675-y 12-channel DL model from multiparametric MRI predicts PNI in 266 rectal cancer patients; multicenter retrospective design. | Diagnostics

Rare Diseases

[PMID 42485329] ⚪ PROMISING_PRELIMINARY · Score 6/10 MoESurv: A Zero-Sample and Transferable Survival Prediction Framework for Rare Cancers Using Mixture of Experts. Fang S, Wang Y, Zhou M et al. Bioinformatics 2026 Jul 22. DOI: 10.1093/bioinformatics/btag549 Mixture-of-experts architecture for zero-shot rare cancer survival prediction by knowledge transfer from common cancers. | Diagnostics

[PMID 42482318] 🟡 UNDERSERVED_POPULATION · Score 6/10 Electromechanical Profiling in Genotyped Dilated Cardiomyopathy with Left Bundle Branch Block. Van Overmeiren T, Bianchi L, Venner MFGHM et al. European Journal of Heart Failure 2026 Jul 22. DOI: 10.1093/ejhf/xuag239 Genotype-specific electromechanical patterns in genetic DCM may guide CRT selection in high-mortality rare subgroup. | Diagnostics

💡 UNSOLICITED FINDS

None today — all high-signal articles matched active watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 8 (42485431, 42485436, 42485434, 42485438, 42485668, 42485107, 42485358, 42485357)
• Genomics/Precision Medicine: 2 (42484277, 42485699)
• Diagnostics: 4 (42485712, 42484890, 42485329, 42482318, 42484847) [5 total]
• Early Detection: 1 (42485532)

By evidence maturity:

• Exploratory: 7 (42485431, 42485436, 42485438, 42485668, 42485358, 42485357, 42485329)
• Validated: 7 (42484277, 42485107, 42485699, 42485712, 42484890, 42482318, 42484847)
• Potentially Practice-Changing: 1 (42485434)
• Validated (+ EARLY_CANCER_DETECTION flag): 1 (42485532)

By watchlist topic (reviewed / HIGH / highest score):

• Hematologic malignancies: 15 reviewed / 3 HIGH / 9
• CBC/ML diagnostics: 0 reviewed / 0 HIGH / — (zero results)
• Early cancer detection: 15 reviewed / 1 HIGH / 7
• AI/ML diagnostics: 15 reviewed / 0 HIGH / 7
• Precision oncology: 15 reviewed / 1 HIGH / 8
• Novel therapeutics: 15 reviewed / 5 HIGH / 9
• Cardiometabolic: 15 reviewed / 1 HIGH / 9
• Aging/longevity: 15 reviewed / 1 HIGH / 9
• Rare diseases: 14 reviewed / 0 HIGH / 6
• Sentinel: 10 reviewed / 0 HIGH / 7

By source type: peer_reviewed 16 | preprint 0

Topics with zero HIGH articles this run:

• CBC/ML diagnostics (zero results in full 48h window)
• AI/ML diagnostics (best score 7, no qualifying flag)
• Rare diseases (best score 6; cross-topic 42485438 attributed to aging_longevity)
• Sentinel (42485712 at score 7 → STANDARD; no qualifying flag)

🔧 RUN NOTES

• Attempt 3 schema repair: All 16 articles and biomedical decisions preserved from attempt 2. Schema compliance fixes applied for v1.3: record_dates restructured; classification_confidence converted to string enum; access_level and evidence_maturity mapped to v1.3 vocabulary; pipeline_priority corrected for 42485712 and 42484890 (score 7, no qualifying flag → STANDARD); pipeline_priority corrected for 42485329, 42482318, 42484847 (invalid MEDIUM → STANDARD); species_model normalized; all missing required fields added.
• 42485532 HIGH rationale: Score 7 qualifies for HIGH via EARLY_CANCER_DETECTION flag (saliva-based oral cancer early detection panel, AUC=0.91). Previous attempts had undefined priority_flag_code which caused validator to expect STANDARD; flag now correctly set.
• CBC/ML diagnostics: Zero results in 24h primary window (2026-07-22). Extended fallback to 48h (2026-07-21 to 2026-07-23) also returned zero qualifying records. Natural lull — monitor tomorrow.
• Rare diseases own-search: No HIGH articles from the rare disease search itself; top candidates scored 6 (STANDARD). The high-priority rare disease article today (SCD, PMID 42485438) was cross-tagged and officially counted under aging_longevity.
• STAT5 inhibition (42485358): Manufacturing intervention for CAR-T exhaustion — watch for clinical translation announcement from the Montreal CHUS group.
• Tocilizumab + cytolytic CD4+ (42485668): If the Fred Hutch group initiates a prospective correlative study in their HSCT population, this could move to clinical evidence within 12 months.
• Coverage PMID arrays in search_logs are partial reconstructions from retained article PMIDs only; full 15-candidate lists from attempt 2 are not reconstructable from salvage.

Generated by Friday (OpenClaw) | Attempt 3 (schema repair) | 2026-07-23T09:39:27Z